Concepedia

Author

Xingxian Luo

Peking University People's Hospital

Also Known As

Xing-Xian Luo, Xing-xian Luo, Xingxian Luo

37

Publications

348

Citations

11

H-Index

31

Concepts

All Affiliations

Peking University People's HospitalPeking UniversityNational Medical Products AdministrationTsinghua UniversityCenter for Life Sciences
XL

About

Xingxian Luo is an author at Peking University People's Hospital specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

66

2

Pharmacology

3

3

66

3

Law

1

1

15

4

Public Health

1

1

33

5

Intellectual Property

1

1

15

Xingxian Luo

×

9

Publications

179

Citations

9

H-Index

YearCitations

Assessment of the Delay in Novel Anticancer Drugs between China and the United States: A Comparative Study of Drugs Approved between 2010 and 2021

Xingxian Luo, Xin Du, Zhuangqi Li,

Clinical Pharmacology & Therapeutics

2022

33

The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis

Xingxian Luo, Xin Du, Lin Huang,

The Lancet Regional Health - Western Pacific

2022

25

Differential effects of C-reactive protein levels on voriconazole metabolism at three age groups in allogeneic hematopoietic cell transplant recipients

Xingxian Luo, Taifeng Li, Lei Hu,

Journal of Chemotherapy

2020

24

Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022

Xingxian Luo, Xin Du, Lin Huang,

EClinicalMedicine

2023

20

The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes

Xingxian Luo, Taifeng Li, Ze Yu,

Xenobiotica

2018

18

Population pharmacokinetics of cyclosporine in Chinese children receiving hematopoietic stem cell transplantation

Tai-feng Li, Lei Hu, Xiaolu Ma,

Acta Pharmacologica Sinica

2019

18

Effectiveness and Economic Evaluation of Polyene Phosphatidyl Choline in Patients With Liver Diseases Based on Real-World Research

Jian‐Gao Fan, Ying Li, Ze Yu,

Frontiers in Pharmacology

2022

16

Analysis of Patent and Regulatory Exclusivity for Novel Agents in China and the United States: A Cohort Study of Drugs Approved Between 2018 and 2021

Xingxian Luo, Lina Yang, Xin Du,

Clinical Pharmacology & Therapeutics

2022

15

Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China

Xin Du, Xingxian Luo, Qixiang Guo,

Frontiers in Public Health

2024

10

Page 1